Neuroretinal Dysfunction With Intact Blood-Retinal Barrier
Transcrição
Neuroretinal Dysfunction With Intact Blood-Retinal Barrier
3926 Diabetes Volume 63, November 2014 Aldina Reis,1,2,3 Catarina Mateus,1 Pedro Melo,1,2 João Figueira,1,2,3 José Cunha-Vaz,1,2,3 and Miguel Castelo-Branco1 Neuroretinal Dysfunction With Intact Blood-Retinal Barrier and Absent Vasculopathy in Type 1 Diabetes COMPLICATIONS Diabetes 2014;63:3926–3937 | DOI: 10.2337/db13-1673 It is unknown whether independent neural damage may occur in the pre-/absent vascular diabetic retinopathy (DR). To exclude vasculopathy, it is important to measure the integrity of the blood-retinal barrier (BRB). This crosssectional study addressed this problem in type 1 diabetic patients with normal ocular fundus and absent breakdown of the BRB (confirmed with vitreous fluorometry). These were compared with a group with disrupted BRB (with normal fundus or initial DR) and normal controls. Multifocal electroretinography and chromatic/achromatic contrast sensitivity were measured in these 42 patients with preserved visual acuity. Amplitudes of neurophysiological responses (multifocal electroretinogram) were decreased in all eccentricity rings in both clinical groups, when compared with controls, with sensitivity >78% for a specificity level of 90%. Implicit time changes were also found in the absence of initial DR. Impaired contrast sensitivity along chromatic axes was also observed, and achromatic thresholds were also different between controls and both clinical groups. The pattern of changes in the group without baseline BRB permeability alterations, as probed by psychophysical and electrophysiological measurements, does thereby confirm independent damage mechanisms. We conclude that retinal neuronal changes can be diagnosed in type 1 diabetes, independently of the breakdown of the BRB and onset of vasculopathy. Diabetic retinopathy (DR) is a major cause of vision loss (1). The prevalence of DR in type 1 diabetic patients is very high (;90% after 15 years of disease duration), as shown by long-term epidemiological studies (2). Among the several known risk factors for DR development, disease duration is indeed one of the most relevant (3–6), together with metabolic control (5,7). Nevertheless, a fraction of patients presenting good metabolic control (;10%) do develop DR, and still another proportion of patients with poor metabolic control, nevertheless, do not develop this complication (8). The role of vasculopathic mechanisms in DR is well established. Accordingly, classification of ocular fundus changes is relevant to the management and treatment of complications of this disease (9–11). The concept of a preretinopathy stage is characterized by the absence of lesions in ocular fundus examination and of the presence of subclinical changes in the blood-retinal barrier (BRB) (3,12,13). Leakage of this barrier has been proposed as the earliest manifestation in DR (3). It is possible that independent neural damage may also occur in diabetes. This is difficult to study in the presence of concomitant vascular damage. However, if early neural damage occurs, it can be studied by searching for evidence of neuroretinal changes in the absence of retinal microvasculopathy. This is possible in the pre-DR stage (14–17). Some functional studies have suggested visual impairment in diabetic patients without apparent DR, but these studies did not exclude changes in integrity of the barrier function using a quantitative method (2,18–25). The occurrence of structural changes indicating vascular damage is also quite disputed in type 1 diabetic patients at a preclinical 1Visual Neuroscience Laboratory, Institute for Biomedical Imaging in Life Sciences, Faculty of Medicine, University of Coimbra, Coimbra, Portugal 2Association for Innovation and Biomedical Research on Light and Image, Coimbra, Portugal 3Coimbra University Hospital, Coimbra, Portugal This article contains Supplementary Data online at http://diabetes .diabetesjournals.org/lookup/suppl/doi:10.2337/db13-1673/-/DC1. Corresponding author: Miguel Castelo-Branco, [email protected]. See accompanying article, p. 3590. Received 29 October 2013 and accepted 6 May 2014. © 2014 by the American Diabetes Association. Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. diabetes.diabetesjournals.org stage (23,26), possibly because the way patients are phenotyped may vary across studies. The criterion for determining the absence of DR lesions in type 1 diabetic patients is indeed a common problem across studies, which often are solely based on retinography or standard angiography. Definition of early vascular (endothelial) changes, as defined above, concerning measures of inner barrier function, may provide a more clear pathophysiological cutoff. Thus we aimed at establishing objective criteria for the absence or presence of initial vasculopathy by including the quantitative measurements of the permeability of the BRB. Type 1 diabetic patients without clinical evidence for DR may show impaired objective responses to stimuli of distinct spatial frequencies (19), sometimes concomitantly associated with different contrast levels (18). A link of such deficits with parvo- and magnocellular impairment is, however, missing. Besides the changes in achromatic contrast sensitivity (20,22), there are also studies showing changed psychophysical and physiologic changes in these patients without DR, related to color contrast sensitivity (24,25) and multifocal electroretinogram (mfERG) responses (21). It remains unclear whether these changes can be present independently of vascular damage (e.g., if they could reflect direct neural damage). The current study aimed to circumvent the abovementioned methodological limitations by providing, as stated above, a clear-cut pathophysiological cutoff between presence and absence of BRB damage (quantitative analysis of BRB permeability with vitreous fluorometry [VF]). We combined this measure with objective structural and functional (electrophysiological) measures of visual function, as well as psychophysical thresholds. In summary, we investigated retinal neural dysfunction in a population of type 1 diabetic patients, from the psychophysical and neurophysiological point of view, with characterization of BRB leakage and metabolic control level. The goal was to identify whether neural damage can occur independently of alterations of the BRB and normal fundus images. RESEARCH DESIGN AND METHODS Patient Selection, Demographic Characteristics, and Ophthalmological Examination The study followed the tenets of the Declaration of Helsinki and was approved by our ethics committee. Prior to the inclusion in the study, informed consent was obtained from all subjects after a full explanation. We tested 42 eyes of 42 patients (mean age 6 SD = 26.6 6 5.3 years) with preserved visual acuity (VA) and divided them into two groups: one group without any clinical signs of DR and normal BRB permeability as assessed by VF (n = 14 eyes; VA = 1.11 6 0.15) and another group with BRB breakdown/vasculopathy with no clinical signs of DR or mild nonproliferative DR (n = 28 eyes; VA = 1.06 6 0.14). These data were compared with those obtained in 25 age-matched controls (27.4 6 5.8 years). Reis and Associates 3927 Sample sizes were sufficient to probe evidence for isolated neural damage as assessed by electrophysiological measures as the main outcome (amplitude of central retinal responses, R1, sample size calculation for a a = 0.05 and power = 0.8; predicted effect size of 30 nV/deg2 between controls and patients, as expected from our previous data and the literature cited in the article’s introduction and DISCUSSION). The criterion for choosing the study eye was the one with larger number of lesions, when applicable. If no DR signs were visible and BRB permeability values were normal, the right eye was chosen if the year of the patient’s birthday was an even number and the left eye if it was an odd number. This last principle (to prevent bias) was also applied to healthy controls. Participants were submitted to a complete ophthalmological examination, including the best-corrected VA, slit lamp examination of anterior chamber, intraocular pressure measurement (Goldmann applanation tonometer), angle and fundus examination (noncontact lens), and subjective visual complaints. Exclusion criteria included media opacities, neuroophthalmological/retinal diseases (besides DR), and high ammetropies (sphere . 64D; cylinder .6 2D). Setting Data were collected at the Institute for Biomedical Imaging in Life Sciences, the Association for Innovation and Biomedical Research on Light and Image, and the University Hospital of Coimbra until 2011. Laboratory Analysis—Glycated Hemoglobin In order to evaluate the patients’ metabolic control level, blood samples were collected for analysis of glycated hemoglobin (HbA1c ). This was assessed by high-performance liquid chromatography (Variant II, Bio-Rad). Characterization of Ocular Fundus and BRB Status Color Fundus Photography Color fundus photographs (35°) of both eyes were taken in seven standard fields of the retina according to Early Treatment Diabetic Retinopathy Study (ETDRS) procedures (9), with a Topcon TRC-50IA Retinal Ophthalmic Camera with a Sony DXC-950P digital camera with a resolution of 0.5 MPixels/768 3 576. These photographs were always obtained after psychophysical and electrophysiological assessment to prevent artifactual changes in retinal adaptation. Fluorescein Angiography Besides color fundus photography, fluorescein angiography (FA) was sequentially performed (TRC-50 IA Topcon; digital camera: B/W Megaplus 1.4i, resolution of 1 MPixel/1,340 3 1,037) to increase sensitivity in detecting topographic changes on BRB permeability. A red-free photograph was taken before 10% fluorescein sodium solution administration, which was injected in the antecubital vein in a volume adjusted to the patients’ weight prior to VF. 3928 Pure Neuroretinal Dysfunction in Diabetes A series of 20 early-phase pictures during the arterial and capillary filling were taken in the eye with larger number of lesions, when applicable. If no DR signs were visible, the right eye was chosen if the year of the patient’s birthday was an even number and the left eye if it was an odd number. After this series, a maculacentered photograph was taken from the contralateral eye, followed by acquisition of quadrantic field images of the selected and the contralateral eyes, respectively. Bilateral late-phase pictures (5 and 10 min) were finally taken in order to first classify in a qualitative manner the presence or absence of leakage to help substantiate the classification of the DR level (10). VF VF is a valuable tool for studying the intraocular fluid dynamics and the permeability of the blood-ocular barriers, namely, the BRB. VF brought an important clinical contribution for quantifying BRB permeability in DR and is of particular interest in the preclinical stage since diabetic eyes show increased permeability values even in apparently normal ocular fundi (27,28). For this purpose, we used a commercial fluorophotometer, the FM-2 Fluorotron Master (Coherent, Palo Alto, CA) and followed the standard protocol for BRB permeability measurement (29). A dose of 14 mg/kg was injected, and measurements of fluorescein concentration in the posterior vitreous were obtained 1 h after injection, after discounting for the natural fluorescence of the ocular tissues (preinjection scan). Blood samples were collected at 10, 15, and 50 min after injection for posterior measurements of the plasmatic fluorescein concentration (a cuvette that was adapted to the optical head of the Fluorotron was used for measuring the concentration of fluorescein in plasmatic solutions). With all these parameters, it was possible to obtain the penetration ratio (PR) of the fluorescein across the BRB (30). Functional Assessment We have applied several psychophysical and electrophysiological methods to characterize visual function and estimate neurophysiological parameters that could be used to study structure-function correlations in our groups. Psychophysics Chromatic Contrast Sensitivity. Chromatic contrast sen- sitivity was tested along three parallel, randomly interleaved staircases (31) (Cambridge Colour Test, CRS, Rochester, U.K.). We simultaneously assessed the three cone confusion axes, modulated in the CIE 1976 u’v’ color space. The chromatic stimulus (a Landolt-like C-shaped ring) appears over the noisy pattern of gray circles of different sizes/luminance levels, and participants chose the gap position in a forced four-choice task. Stimuli were presented monocularly on a 21-inch g-corrected monitor (GDM-F520; Sony, Tokyo, Japan; refresh rate 100 Hz) at a viewing distance of 1.8 m in a darkened room. Far vision refractive correction was worn by participants, Diabetes Volume 63, November 2014 and tinted contact/spectacle lenses were replaced by lenses in a trial frame when necessary. The test ended after 11 reversals of each adaptive staircase, and the mean of the last 7 reversals was obtained as the threshold expressed in confusion vector length for each protan, deutan, and tritan axes in CIE 1976 u’v’ color space units (32,33). Achromatic Contrast Sensitivity. Achromatic contrast sen- sitivity within the magnocellular pathway was probed using a perimetric test based on frequency-doubling technology (FDT) (33–35). Vertically oriented sinusoidal grating stimuli (0.25 cpd, 25 Hz) were presented monocularly using a Humphrey Matrix Perimeter (Carl Zeiss Meditec Inc.). An N-30-F (nasal 30°) threshold testing strategy was chosen. This procedure consisted of a modified binary search using a four-reversal rule to determine the threshold level at each of the 19 tested locations. The range of possible raw data are between 0 dB (maximum contrast/ lowest patient sensitivity) and 56 dB. The formula to calculate sensitivity in dB units was log10*(2,048/c)*10*H, where c ranges from 1 to 2,048 (scaled minimum and maximum contrast, respectively) and H (Humphrey scaling factor) is ;2. Statistical analysis was performed considering both global parameters (mean deviation [MD] and pattern SD [PSD]) and contrast sensitivity pooled from five regions: the 5° central area (C) and the four visual field quadrants (superior temporal [ST], superior nasal [SN], inferior nasal [IN], and inferior temporal [IT]). Neurophysiology The electrophysiological procedures mentioned below were performed with pupil dilation. mfERG mfERG was recorded using RETIscan (Roland Consult, Germany) with DTL-Plus electrodes to measure local photopic activity within photoreceptor/bipolar cell circuitry (36). The stimulus consisted in a 30° central visual field hexagonal pattern with 61 elements adjusted for the magnification factor, pseudo-randomly presented binocularly according to the standard m-sequence on a 20-inch cathode ray tube monitor (rate 60 Hz; viewing distance 33 cm). Participants’ far vision refractive correction was compensated, when applicable, according to the adjustment scale for this purpose, and near refractive correction was added if necessary. Active voltage range of the signal was 6200 mV using a band-pass filter of 5–100 Hz and amplification at a gain of 100,000. Eight 47-s cycles were obtained for averaging at an artifact rejection level of 10%. Analyses were performed using the first-order kernels. For each hexagon and concentric ring (eccentricities, in diameter of visual angle: ring 1, 4.4°; ring 2, 4.4–13.6°; ring 3, 13.6–25.8°; ring 4, 25.8–40.8°; ring 5, 40.8–58.7°), the amplitude (nV/deg2) and implicit times (ms) of the N1 trough and the P1 peak were calculated. diabetes.diabetesjournals.org Reis and Associates Table 1—Demographic and clinical characterization of the 42 included diabetic patients HbA1c Age (years) Diabetes duration (years) % mmol/ mol Vascular lesions (no/yes) ETDRS grading (study eye) 1 29 12 6.6 49 No 10 2 28 17 8.4 68 Yes 20 3 25 15 6.2 44 No 10 4 23 15 8.7 72 Yes 20 5 25 12 7.2 55 No 10 6 14 7 7.8 62 No 10 7 15 13 9.6 81 Yes* 10 8 25 17 9.3 78 Yes* 10 9 30 24 7.0 53 No 10 10 23 12 11.6 103 Yes 35D 11 26 15 8.7 72 No 10 12 27 15 13.0 119 Yes 35D 13 28 17 11.1 98 Yes 20 14 29 14 6.7 50 No 10 15 28 18 10.0 86 Yes 20 16 25 17 7.6 60 Yes 20 17 16 12 9.9 85 No 10 18 23 12 6.8 51 No 10 19 25 17 6.5 48 Yes 20 20 31 27 8.1 65 Yes 35D 21 29 24 9.1 76 No 10 22 29 22 9.1 76 Yes 35D 23 23 10 8.9 74 No 10 24 33 22 7.3 56 Yes 35C 25 27 19 7.3 56 No 10 26 29 21 8.1 65 Yes 20 27 19 13 7.6 60 No 10 28 24 14 6.4 46 Yes* 10 29 31 15 8.2 66 Yes 20 30 23 12 8.4 68 Yes 20 31 18 16 7.9 63 Yes 20 32 31 13 8.0 64 Yes 35D 33 29 25 7.1 54 Yes 20 34 35 19 6.9 52 Yes 20 35 37 29 8.9 74 Yes 35D 36 34 26 10.1 87 Yes 20 37 35 25 6.5 48 Yes 35C 38 32 29 7.4 57 Yes 20 39 24 17 8.6 70 Yes 35C 40 29 13 8.5 69 No 10 41 22 20 11.1 98 Yes 35C 42 31 20 9.6 81 Yes 20 Patient ID *Criterion for vascular lesions based on VF results. 3929 3930 Pure Neuroretinal Dysfunction in Diabetes Statistical Analysis Given the observed relative violation of ANOVA assumptions, nonparametric analyses (Mann-Whitney U testing/ Spearman rank correlation) at a significance level of P , 0.05 were performed using StatView (SAS, Cary, NC), with correction for the number of group comparisons. Given the conservative approach of only including one eye per participant (see RESEARCH DESIGN AND METHODS), we also replicated this analysis with an approach that uses all eyes, with correction for dependence using generalized estimating equations (see Supplementary Data with this replication analysis). Receiver operating characteristic (ROC) analyses (MedCalc, version 12.2.1.0, Mariakerke, Belgium) were performed to determine sensitivities at defined levels of specificity (;90%) and to compare differences between controls and patients without signs of DR and preserved BRB. Diagnostic accuracies of psychophysical and electrophysiological tests were assessed by comparing areas under the ROC curves (AUCs). Statistic significance was set at P , 0.05. RESULTS Table 1 provides a global summary of the demographic and clinical data of the included diabetic patients (age, diabetes duration, HbA1c, and presence/degree of vascular ocular fundus lesions). Group analyses are presented below. Demographic Characteristics and Ophthalmological Characterization The study group included 42 eyes of 42 type 1 diabetic patients (14–37 years; mean age 6 SD = 26.6 6 5.3 years) with preserved VA (best-corrected values ranging from 0.9 to 1.3) divided into two subgroups according to the values of BRB permeability assessed by VF and the ETDRS classification system (based on color fundus photography and FA analysis): one group with normal BRB permeability (#3.1 3 1026 min21) and no fundus signs of DR (n = 14 eyes; VA = 1.11 6 0.15) and another group that included patients with mild nonproliferative DR, or no DR but increased BRB permeability values (n = 28 eyes; VA = 1.06 6 0.14). The mean duration of disease ranged from 7 to 29 years (group with no DR, mean 6 SD = 14.43 6 4.86 years; group with initial DR, mean 6 SD = 18.93 6 5.04 years). All participants completed the protocol, so no cases of missing data were present. Diabetes Volume 63, November 2014 to 9.9% (85 mmol/mol; mean 6 SD values = 7.74 6 1.11% [61 6 12.1 mmol/mol]). In the group with disruption of BRB, HbA1c varied from 6.2% (44 mmol/mol) to 13.0% (119 mmol/mol; mean 6 SD values = 8.70% 6 1.64% [72 6 17.9 mmol/mol]). This difference did not reach statistical significance (P = 0.07). Characterization of BRB Status Color Fundus Photography and FA These two methods were jointly used to classify the DR level: 10 (17 eyes, 40.5%), 20 (15 eyes, 36%), 35C (4 eyes, 9.5%), and 35D (6 eyes, 14%). See Table 1 for more details (right column). Measures of BRB Permeability Using VF In the group with disrupted BRB, PR values (1026 min21) ranged from 1.78 to 12.39 (mean 6 SD = 4.78 6 2.79), while in the other group, these values ranged from 1.08 to 2.81 (mean 6 SD = 2.12 6 0.49). These are below the limit for normal values (#3.1 3 1026 min21) identified in the literature, thereby enabling us to define the participants in this group as having normal BRB permeability (37) according to the inclusion criteria. Table 2 provides a detailed characterization of the diabetic group characterized by no changes in BRB and, simultaneously, by the absence of signs of DR. Functional Assessment Figure 1 shows different examples of psychophysical and neurophysiological data in three patients with different patterns of damage (patients 5 and 29 present no DR, patient 5 with minimal functional changes and patient 29 with clear impairment on visual function testing; patient 4 had initial DR). Table 2—Characterization of the diabetic patient group with no changes in BRB (£3.1 3 1026 min21) and DR ETDRS grading of 10 VA Disease BRB PR (study duration (study Patient Sex eye) (years) eye) 1 Male 1.3 12 1.88 3 Male 1.3 15 1.72 5 Male 1.0 12 1.53 6 Female 1.0 7 2.81 9 Male 1.3 24 1.82 11 Male 1.3 15 2.20 14 Male 1.3 14 1.08 17 Male 1.0 12 2.34 Analysis of Metabolic Control—HbA1c 18 Male 1.0 12 2.64 These patients had thorough and systematic local surveillance of metabolic control levels since childhood, at the time of their diagnosis of diabetes: one visit to the endocrinology department, every 6 months in the initial follow-up, and one visit yearly thereafter. In the group with normal BRB, HbA1c varied from 6.2% (44 mmol/mol) 21 Female 1.0 24 1.91 23 Male 1.0 10 2.63 25 Male 1.0 19 2.05 27 Female 1.0 13 2.50 40 Female 1.0 13 2.51 diabetes.diabetesjournals.org Reis and Associates 3931 Figure 1—Representative examples of some results of two patients without DR (patient 5 without DR and minimal changes on functional testing; patient 29 without DR with more changes than patient 5) and a patient with initial DR (patient 4), with three microaneurisms identified. A: FA. B: Achromatic contrast sensitivity (FDT). C: Standard mfERG (C1: plots; C2: analysis by concentric rings). Psychophysics Chromatic Contrast Sensitivity—Evidence for Damage of Both Parvocellular and Koniocellular Pathways Even in Patients with Absent Leakage and DR. As illustrated in Fig. 2, chromatic contrast sensitivity measures were significantly different between controls and patients. Considering the group with disrupted BRB, the comparison with controls showed higher thresholds for all chromatic axes (protan, P = 0.007; deutan, P , 0.0001; tritan, P , 0.0001). Importantly, significantly higher thresholds were also found, but only for the tritan axis in the group with normal BRB permeability and no DR (P = 0.009). When comparing both patient groups, significant differences are only found for the deutan axis (P = 0.01). Achromatic Contrast Sensitivity—Evidence for Early Magnocellular Impairment. MD, a global parameter of magnocellular performance (FDT testing; see RESEARCH yielded significant differences between controls and each group of patients (with normal BRB permeability and no DR, P = 0.002; with leakage and/or DR, P = 0.0002), with no significant effect detected between patient groups. Concerning PSD (field heterogeneity measure), a significant difference was found between controls and patients with diabetes without leakage and no DR (P = 0.02) and no difference between patients groups. For details, see Fig. 3A. Please note that MD and PSD provide essentially different information, and MD is more useful as a lesion indicator since it defines absolute/global damage. This value is higher in the group of initial DR, as expected. DESIGN AND METHODS) 3932 Pure Neuroretinal Dysfunction in Diabetes Diabetes Volume 63, November 2014 Figure 2—Chromatic contrast thresholds in patients and in controls, where impairment can be already observed in the group with no DR and normal BRB permeability. Percentile data depicted. mNPDR, mild nonproliferative DR. To probe whether regional differences were underlying these effects, we then analyzed magnocellular achromatic contrast sensitivity in distinct regions. Significant differences were found in all five locations, between controls and both patient groups, except in the C region and IT quadrant of the visual field in patients with no lesions (group with preserved BRB and no DR: ST, P = 0.04; SN, P = 0.01; IN, P = 0.058—group with disrupted BRB: C, P = 0.02; ST, P = 0.01; SN, P = 0.003; IN, P , 0.0001). Comparisons between both patient groups showed no significant differences (see Fig. 3B for details). Neurophysiology mfERG—Direct Evidence for Neural Dysfunction in the Absence of Leakage and DR. The mfERG showed a signif- icant decrease in amplitude in all concentric rings in both patient groups when compared with control subjects (P1 wave, all eccentricity rings, P , 0.0001 in the group of Figure 3—Magnocellular contrast sensitivity expressed in whole-field deviation (MD) and in regional homogeneity (PSD) measures in patients and in controls (A), as well as in quadrantic thresholds (B). Percentile data depicted. mNPDR, mild nonproliferative DR; Temp. Sup., ST; Nasal Sup., SN; Nasal Inf., IN; Temp. Inf., IT. diabetes.diabetesjournals.org disrupted BRB—group with preserved BRB, R1, P , 0.0001; R2, P = 0.0003; R3–R5, P , 0.0001) (Fig. 4A), suggesting a neural basis for damage at the outer retinal level (photoreceptor and bipolar cell circuit level) since dysfunction occurs irrespective of evidence for early vascular damage. Analysis of implicit times showed a significant decrease in patients with preserved BRB and no DR, as compared with controls, but only in ring 2 (P = 0.006). This difference is also evident in ring 2 (P = 0.02) in the group with disrupted BRB (see Fig. 4B for details). A similar pattern was found concerning the N1 component: decrease in amplitude values in both patient groups (with disrupted BRB, R2, P = 0.001; R3, P = 0.0003; R4, P = 0.0006; R5, P , 0.0001—with preserved BRB, rings 2–5, P , 0.0001), with no changes in implicit times (Fig. 5A and B). It is important to point out that no significant differences were obtained for amplitude and implicit time values of P1 and N1 waves between both clinical groups. Structure and Function Correlations Correlations with BRB Permeability Significant correlations could be observed between PR and functional measures in the group with leakage, namely, in chromatic thresholds (deutan, r = 0.39, P = 0.04; tritan, r = 0.37, P = 0.05) and in mfERG P1-wave implicit time (most peripheral rings, R5, r = 0.46, P = 0.002). Reis and Associates 3933 Correlations with Duration of Diabetes Duration of disease correlated with implicit time of mfERG, namely, P1 wave (most peripheral rings, R4, r = 0.43, P = 0.03; R5, r = 0.44, P = 0.02; and marginally lost in ring 1, r = 0.25, P = 0.06) and N1 wave (ring 1, r = 0.44, P = 0.02), in the group with BRB changes. In the other clinical group, duration of diabetes only correlates with a chromatic protan thresholds axis: r = 0.72, P = 0.002. These findings suggest distinct pathophysiological mechanisms in the presence or absence of BRB breakdown. ROC Curve—Sensitivity/Specificity Analysis ROC curves were generated for all included tests, allowing us to compare sensitivities (probability of positive testing results when the clinical condition is present) for detecting impairment at fixed specificity levels. In our analysis, the chosen cutoff for this parameter was set near 90%. The highest sensitivity values were found in mfERG amplitude values (P1 wave, sensitivities of 78% across the five concentric rings). N1 wave amplitude values also showed high sensitivities (up to 82%) in paracentral rings, except in the central ring. Chromatic contrast tests showed the lowest sensitivity, in particular, concerning protan and deutan axes (Table 3 and Fig. 6). Figure 4—P1 wave amplitude (A) and implicit time (B) of mfERG across concentric rings. Decreased amplitude values are found in both patient groups, showing a different pattern in implicit time (decreased values in the group with no DR). Percentile data depicted. mNPDR, mild nonproliferative DR. 3934 Pure Neuroretinal Dysfunction in Diabetes Diabetes Volume 63, November 2014 Figure 5—N1 wave amplitude (A) and implicit time (B) of mfERG across concentric rings. Percentile data depicted. mNPDR, mild nonproliferative DR. Diagnostic Accuracy by AUC The AUC summarizes the diagnostic accuracy of each parameter (AUC = 1 would represent a perfect discrimination between controls and diabetic patients with no signs of DR/preserved BRB; AUC = 0.5 means discrimination at the chance level). Our results showed AUCs between 0.946 and 0.532 (Table 3). The higher AUC values (P , 0.0001) correspond to the mfERG test (P1 and N1 wave amplitudes, except ring 1 of the N1 wave). DISCUSSION In this study, we have found evidence for an independent neural phenotype in pre- or absent vascular DR in type 1 diabetes. This was possible to establish by using a clear pathophysiological cutoff defining the onset of endothelial lesions. This cutoff is based on in vivo objective measures of BRB permeability. Retinal neuronal changes occurring in type 1 diabetic patients with no breakdown of the BRB or onset of vasculopathy were probed by psychophysical (achromatic/ chromatic contrast sensitivity) tests of ganglion cell magno-, parvo- and koniocellular pathways and electrophysiological recordings (mfERG). The latter suggest a neural correlate of dysfunction at the outer retina. Interestingly, we found that neurophysiological changes correlate with increased BRB permeability in the group of patients with leakage, which confirms the existence of an independent mechanism in the absence of BRB disruption. This corroborates the idea that isolated neural damage can occur even when the (usually dominant) vascular damage is not present. The fact that these measures were more tightly linked with disease time duration in the group with vascular lesions suggests that vascular damage superimposed on primary and secondary neuronal changes can dominate during the subsequent period in the natural history of disease. These issues can best be clarified in a longitudinal study. Concerning the functional pathways that were affected even in the prevascular stage, we identified damage of both parvocellular and koniocellular pathways (as demonstrated by chromatic contrast sensitivity testing). Some previous studies also report significant color vision defects in type 1 diabetes (24,25). However, these studies did not provide a clear cutoff between prevascular and vascular stages. Impairment of magnocellular function was also observed (as revealed by decreased thresholds in FDT in C and peripheral regions), even in the group with normal BRB measures and without clinical signs of DR. Previous studies reported a nonselective decrease in contrast sensitivity (18,19,22,38). Our study used a specific perimetric test biased to the activation of the magnocellular performance, probing central and peripheral vision, and our results are consistent with a previous study documenting diabetes.diabetesjournals.org Reis and Associates 3935 Table 3—AUC and associated 95% CI for the studied testing variables comparing controls and diabetic patients with ETDRS grading of 10 and preserved BRB Parameters AUC 95% CI P value Sensitivity/ specificity (%) Criterion value for 90% specificity Cambridge Colour Test Protan Deutan Tritan 0.646 0.586 0.794 0.498–0.776 0.438–0.724 0.656–0.895 0.1164* 0.3893* 0.0001 21/89 14/89 50/89 51 49 73 FDT MD PSD C ST SN IN IT 0.805 0.738 0.691 0.721 0.760 0.711 0.670 0.676–0.899 0.602–0.847 0.552–0.808 0.584–0.834 0.625–0.865 0.573–0.825 0.530–0.791 ,0.0001 0.0072 0.03189 0.0098 0.0020 0.0118 0.0540 43/90 57/90 36/88 50/90 50/90 36/90 36/93 21.51 4.26 29.50 28.38 29.00 29.60 29.50 ERG—P1 amplitude Ring 1 Ring 2 Ring 3 Ring 4 Ring 5 0.938 0.867 0.900 0.912 0.921 0.822–0.988 0.730–0.950 0.772–0.970 0.787–0.976 0.799–0.981 ,0.0001 ,0.0001 ,0.0001 ,0.0001 ,0.0001 79/90 79/90 79/90 71/90 79/90 63.1 33.87 22.76 13.74 10.40 ERG—P1 IT Ring 1 Ring 2 Ring 3 Ring 4 Ring 5 0.500 0.790 0.721 0.693 0.702 0.346–0.654 0.641–0.898 0.566–0.846 0.536–0.823 0.546–0.831 1.0000* 0.0011 0.0169 0.0478 0.0272 14/93 71/90 50/90 50/90 43/90 42.4 34.38 33.69 32.91 33.23 ERG—N1 amplitude Ring 1 Ring 2 Ring 3 Ring 4 Ring 5 0.721 0.881 0.912 0.926 0.891 0.562–0.848 0.743–0.960 0.784–0.977 0.801–0.984 0.757–0.966 0.0201 ,0.0001 ,0.0001 ,0.0001 ,0.0001 46/90 85/90 85/90 85/90 85/90 11.20 9.59 7.12 4.18 3.54 ERG—N1 IT Ring 1 Ring 2 Ring 3 Ring 4 Ring 5 0.580 0.715 0.586 0.554 0.603 0.418–0.730 0.555–0.843 0.424–0.736 0.393–0.708 0.441–0.751 0.5013* 0.0302 0.3982* 0.5869* 0.3576* 39/93 46/90 31/93 15/90 31/86 18.75 13.80 12.80 12.80 13.30 Sensitivities were obtained for each parameter at ;90% specificity. Criterion values related with this specificity are also presented. mfERG results (in particular, the P1 wave amplitude) show the highest sensitivity values for a fixed specificity (;90%). *Nonsignificant values. FDT changes in diabetic patients with no clinically detectable DR (39,40). mfERG findings showed generalized decrease amplitudes that are consistent with changes at photoreceptor/bipolar cell circuits. Recent studies (41–43) reported local neurophysiological changes in type 1 diabetes, as assessed by mfERG. Although these local neurophysiological changes show the expected interindividual variability (in terms of range of amplitude values), ROC and AUC analyses showed that relatively high sensitivity is observed for electrophysiological measures at high specificities, confirming the presence of sensitive early measures of specific neural damage that may potentially be used as biomarkers for detecting neural changes independently of vascular lesions. Accordingly, studies by the Adams group have shown that local mfERGs are highly predictive of the subsequent development of DR in adult patients, suggesting the location of future lesions, based on previous local changes in implicit time (44–46). In our study, we also found early mfERG changes. However, these are not directly comparable to the abovementioned results because of group definition criteria. Changes in wave morphology and amplitude might lead to different forms of change and even decreases in the local implicit time values, especially in cases of amplitude reduction. However, in patients with minimal DR, implicit time tended to increase. As mentioned above, small differences across studies might be due to the criterion for defining the absence of retinal lesions. In previous studies, it was based on fundus photography and not on an increase in BRB permeability, which is the first sign of vascular damage (3,12,13). In other words, BRB permeability 3936 Pure Neuroretinal Dysfunction in Diabetes Diabetes Volume 63, November 2014 Figure 6—ROC curves generated for mfERG (P1 wave amplitude of the five concentric rings) depicting that relatively high sensitivity values correspond to a specificity of 71–79%, with AUC ;0.9. measurements may be critical to precisely define the presence or absence of a vascular phenotype. In summary, our study uniquely combined objective measures of the BRB permeability and DR staging to define diabetic patient groups with and without vascular damage. A neural phenotype could then be investigated with functional information gathered from psychophysical and neurophysiological measures. We found that these could discriminate between groups with high sensitivity and specificity, as confirmed by ROC analyses, which support the generalizability of our results. These findings show that neural changes may probably occur in the retina in addition to and independently of vascular lesions, with potential implications for early neuroprotective treatment (47). The main limitation of this study is that it is crosssectional and cannot infer on the relative time courses of neural and vascular processes. Moreover, the BRB permeability assay may be differently sensitive to vascular pathology in different regions of the retina when compared with retinal function testing across broad regions. Future longitudinal studies should elucidate the time course of isolated diabetes-related neural impairment in relation to the likely dominant neural phenotype secondary to vascular damage that is also present in the natural history of DR. We conclude that retinal neuronal changes can occur in type 1 diabetic patients independently of the breakdown of the BRB or vasculopathy. Funding. This research was supported by Fundação para a Tecnologia: FCT/ PTDC/SAU/NEU/68483/2006, COMPETE/PEst-C/SAU/UI3282/2013; the National Brain Imaging Network of Portugal, Comissão de Coordenação Região Centro, CENTRO-07-ST24-FEDER-00205; and Agência de Inovação, QREN-COMPETE/ DoIT/Diamarker. Duality of Interest. No potential conflicts of interest relevant to this article were reported. Authors Contributions. A.R. designed the experiments, acquired and analyzed data, and wrote and edited the manuscript. C.M. acquired and analyzed data. P.M. and J.F. acquired data. J.C.-V. contributed to the discussion. M.C.-B. designed the experiments, analyzed data, contributed to the discussion, and wrote the manuscript. A.R. and M.C.-B. are the guarantors of this work and, as such, had full access to all the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis. References 1. Klein BE. Overview of epidemiologic studies of diabetic retinopathy. Ophthalmic Epidemiol 2007;14:179–183 2. Klein R, Knudtson MD, Lee KE, Gangnon R, Klein BE. The Wisconsin Epidemiologic Study of Diabetic Retinopathy: XXII the twenty-five-year progression of retinopathy in persons with type 1 diabetes. Ophthalmology 2008;115:1859– 1868 3. Cunha-Vaz JG. Clinical Presentation of Retinopathy. In Diabetic Retinopathy. Cunha-Vaz JG, Ed. Singapore, World Scientific Publishing, 2011, p. 37–50 4. Williams R, Airey M, Baxter H, Forrester J, Kennedy-Martin T, Girach A. Epidemiology of diabetic retinopathy and macular oedema: a systematic review. Eye (Lond) 2004;18:963–983 5. Henricsson M, Nyström L, Blohmé G, et al. The incidence of retinopathy 10 years after diagnosis in young adult people with diabetes: results from the nationwide population-based Diabetes Incidence Study in Sweden (DISS). Diabetes Care 2003;26:349–354 6. Likitmaskul S, Wacharasindhu S, Rawdaree P, et al. Thailand diabetes registry project: type of diabetes, glycemic control and prevalence of microvascular complications in children and adolescents with diabetes. J Med Assoc Thai 2006;89(Suppl. 1):S10–S16 7. Kullberg CE, Abrahamsson M, Arnqvist HJ, Finnström K, Ludvigsson J; VISS Study Group. Prevalence of retinopathy differs with age at onset of diabetes in a population of patients with type 1 diabetes. Diabet Med 2002;19:924–931 8. Zhang L, Krzentowski G, Albert A, Lefebvre PJ. Risk of developing retinopathy in Diabetes Control and Complications Trial type 1 diabetic patients with good or poor metabolic control. Diabetes Care 2001;24:1275–1279 9. Early Treatment Diabetic Retinopathy Study Research Group. Grading diabetic retinopathy from stereoscopic color fundus photographs–an extension of diabetes.diabetesjournals.org the modified Airlie House classification. ETDRS report number 10. Ophthalmology 1991;98(5 Suppl.): 786–806 10. Early Treatment Diabetic Retinopathy Study Research Group. Classification of diabetic retinopathy from fluorescein angiograms. ETDRS report number 11. Ophthalmology 1991;98(5 Suppl.):807–822 11. Early Treatment Diabetic Retinopathy Study Research Group. Treatment techniques and clinical guidelines for photocoagulation of diabetic macular edema. Early Treatment Diabetic Retinopathy Study Report Number 2. Ophthalmology 1987;94:761–774 12. Lobo CL, Bernardes RC, Cunha-Vaz JG. Alterations of the blood-retinal barrier and retinal thickness in preclinical retinopathy in subjects with type 2 diabetes. Arch Ophthalmol 2000;118:1364–1369 13. Ludovico J, Bernardes R, Pires I, Figueira J, Lobo C, Cunha-Vaz J. Alterations of retinal capillary blood flow in preclinical retinopathy in subjects with type 2 diabetes. Graefes Arch Clin Exp Ophthalmol 2003;241:181–186 14. Barber AJ. A new view of diabetic retinopathy: a neurodegenerative disease of the eye. Prog Neuropsychopharmacol Biol Psychiatry 2003;27:283–290 15. Santiago AR, Rosa SC, Santos PF, Cristóvão AJ, Barber AJ, Ambrósio AF. Elevated glucose changes the expression of ionotropic glutamate receptor subunits and impairs calcium homeostasis in retinal neural cells. Invest Ophthalmol Vis Sci 2006;47:4130–4137 16. Santiago AR, Pereira TS, Garrido MJ, Cristóvão AJ, Santos PF, Ambrósio AF. High glucose and diabetes increase the release of [3H]-D-aspartate in retinal cell cultures and in rat retinas. Neurochem Int 2006;48:453–458 17. Leal EC, Santiago AR, Ambrósio AF. Old and new drug targets in diabetic retinopathy: from biochemical changes to inflammation and neurodegeneration. Curr Drug Targets CNS Neurol Disord 2005;4:421–434 18. Lopes de Faria JM, Katsumi O, Cagliero E, Nathan D, Hirose T. Neurovisual abnormalities preceding the retinopathy in patients with long-term type 1 diabetes mellitus. Graefes Arch Clin Exp Ophthalmol 2001;239:643–648 19. Di Leo MA, Falsini B, Caputo S, Ghirlanda G, Porciatti V, Greco AV. Spatial frequency-selective losses with pattern electroretinogram in type 1 (insulindependent) diabetic patients without retinopathy. Diabetologia 1990;33:726–730 20. Lecleire-Collet A, Audo I, Aout M, et al. Evaluation of retinal function and flicker light-induced retinal vascular response in normotensive patients with diabetes without retinopathy. Invest Ophthalmol Vis Sci 2011;52:2861–2867 21. Fortune B, Schneck ME, Adams AJ. Multifocal electroretinogram delays reveal local retinal dysfunction in early diabetic retinopathy. Invest Ophthalmol Vis Sci 1999;40:2638–2651 22. Krásný J, Brunnerová R, Průhová S, et al. The contrast sensitivity test in early detection of ocular changes in children, teenagers, and young adults with diabetes mellitus type I. Cesk Slov Oftalmol 2006;62:381–394 [in Czech] 23. van Dijk HW, Verbraak FD, Stehouwer M, et al. Association of visual function and ganglion cell layer thickness in patients with diabetes mellitus type 1 and no or minimal diabetic retinopathy. Vision Res 2011;51:224–228 24. Giusti C. Lanthony 15-Hue Desaturated Test for screening of early color vision defects in uncomplicated juvenile diabetes. Jpn J Ophthalmol 2001;45: 607–611 25. Mulak M, Reniewska B, Kostuś E, Balcewicz A, Misiuk-Hojło M. The role of color vision disturbances in diagnostics of early diabetic retinopathy. Klin Oczna 2002;104:249–251 [in Polish] 26. Ciresi A, Amato MC, Morreale D, et al. OCT is not useful for detection of minimal diabetic retinopathy in type 1 diabetes. Acta Diabetol 2010;47:259–263 27. Cunha-Vaz J, Faria de Abreu JR, Campos AJ. Early breakdown of the bloodretinal barrier in diabetes. Br J Ophthalmol 1975;59:649–656 28. Waltman SR, Oestrich C, Krupin T, et al. Quantitative vitreous fluorophotometry. A sensitive technique for measuring early breakdown of the blood-retinal barrier in young diabetic patients. Diabetes 1978;27:85–87 Reis and Associates 3937 29. Gray JR, Mosier MA, Ishimoto BM. Optimized protocol for Fluorotron Master. Graefes Arch Clin Exp Ophthalmol 1985;222:225–229 30. Zeimer RC, Blair NP, Cunha-Vaz JG. Vitreous fluorophotometry for clinical research. II. Method of data acquisition and processing. Arch Ophthalmol 1983; 101:1757–1761 31. Regan BC, Reffin JP, Mollon JD. Luminance noise and the rapid determination of discrimination ellipses in colour deficiency. Vision Res 1994;34: 1279–1299 32. Castelo-Branco M, Faria P, Forjaz V, Kozak LR, Azevedo H. Simultaneous comparison of relative damage to chromatic pathways in ocular hypertension and glaucoma: correlation with clinical measures. Invest Ophthalmol Vis Sci 2004;45: 499–505 33. Reis A, Mateus C, Macário MC, de Abreu JR, Castelo-Branco M. Independent patterns of damage to retinocortical pathways in multiple sclerosis without a previous episode of optic neuritis. J Neurol 2011;258: 1695–1704 34. White AJ, Sun H, Swanson WH, Lee BB. An examination of physiological mechanisms underlying the frequency-doubling illusion. Invest Ophthalmol Vis Sci 2002;43:3590–3599 35. Kelly DH. Frequency doubling in visual responses. J Opt Soc Am 1966;56: 1628–1633 36. Hood DC, Bach M, Brigell M, et al.; International Society For Clinical Electrophysiology of Vision. ISCEV Standard for clinical multifocal electroretinography (mfERG) (2011 edition). Doc Ophthalmol 2012;124:1–13 37. Cunha-Vaz JG, Gray JR, Zeimer RC, Mota MC, Ishimoto BM, Leite E. Characterization of the early stages of diabetic retinopathy by vitreous fluorophotometry. Diabetes 1985;34:53–59 38. Georgakopoulos CD, Eliopoulou MI, Exarchou AM, Tzimis V, Pharmakakis NM, Spiliotis BE. Decreased contrast sensitivity in children and adolescents with type 1 diabetes mellitus. J Pediatr Ophthalmol Strabismus 2011;48:92–97 39. Jackson GR, Scott IU, Quillen DA, Walter LE, Gardner TW. Inner retinal visual dysfunction is a sensitive marker of non-proliferative diabetic retinopathy. Br J Ophthalmol 2012;96:699–703 40. Parravano M, Oddone F, Mineo D, et al. The role of Humphrey Matrix testing in the early diagnosis of retinopathy in type 1 diabetes. Br J Ophthalmol 2008;92: 1656–1660 41. Lakhani E, Wright T, Abdolell M, Westall C. Multifocal ERG defects associated with insufficient long-term glycemic control in adolescents with type 1 diabetes. Invest Ophthalmol Vis Sci 2010;51:5297–5303 42. Bronson-Castain KW, Bearse MA Jr, Neuville J, et al. Early neural and vascular changes in the adolescent type 1 and type 2 diabetic retina. Retina 2012;32:92–102 43. Laron M, Bearse MA Jr, Bronson-Castain K, et al. Association between local neuroretinal function and control of adolescent type 1 diabetes. Invest Ophthalmol Vis Sci 2012;53:7071–7076 44. Han Y, Schneck ME, Bearse MA Jr, et al. Formulation and evaluation of a predictive model to identify the sites of future diabetic retinopathy. Invest Ophthalmol Vis Sci 2004;45:4106–4112 45. Ng JS, Bearse MA Jr, Schneck ME, Barez S, Adams AJ. Local diabetic retinopathy prediction by multifocal ERG delays over 3 years. Invest Ophthalmol Vis Sci 2008;49:1622–1628 46. Harrison WW, Bearse MA Jr, Ng JS, et al. Multifocal electroretinograms predict onset of diabetic retinopathy in adult patients with diabetes. Invest Ophthalmol Vis Sci 2011;52:772–777 47. Simó R, Hernández C; European Consortium for the Early Treatment of Diabetic Retinopathy (EUROCONDOR). Neurodegeneration is an early event in diabetic retinopathy: therapeutic implications. Br J Ophthalmol 2012;96:1285– 1290
Documentos relacionados
Urinary loss of micronutrients in diabetic patients attending a tertiary
The objective of the present study was to determine the urinary excretion of micronutrients in diabetic patients followed up at a university hospital. The excess weight of the diabetic group agreed...
Leia maisARVO 2012 Annual Meeting Abstracts
manifestation of the same disease.Mutations in the ABCA4 gene were associated with both. Recently, fundus autofluorescence (AF) has been used extensively to study STGD / FF. Most reported imaging i...
Leia mais